Categories: CancerNews

Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase

Agreement aims to enhance Pillar’s PiVAT® bioinformatics platform with downstream reporting capabilities.

NATICK, Mass., Jan. 7, 2025 /PRNewswire/ — Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) for its proprietary OncoKB precision medicine knowledgebase.

OncoKBis the first somatic human variant database to receive FDA recognition. It contains information about the biological effects and possible treatment implications of specific cancer gene alterations. 

The strategic licensing agreement enables immediate extension of the capability of Pillar Biosciences PiVAT® bioinformatics platform for seamless patient genomic reporting through linkage to OncoKB.  

“Our PiVAT® secondary genomics analysis platform was purpose built for our SLIMamp® chemistry to enable the most accurate genomic calling for our kitted RUO and IVD products,” said ShiPing Zou, Senior Director of Global Product Management, Pillar Biosciences. “While Pillar’s panels are agnostic to which tertiary reporting our clients have implemented, it is important we ensure that downstream genomic reporting is not a bottleneck to assay validation and implementation and that we continue to provide timely access to actionable information to our customers and the patients they serve.”

About Pillar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pillar-biosciences-enters-into-strategic-licensing-agreement-for-msks-oncokb-precision-medicine-knowledgebase-302338477.html

SOURCE Pillar Biosciences, Inc.

Staff

Recent Posts

Olympian Gabby Thomas Draws Crowd at Wellness Event with BetterWay(TM) Blood Testing at H-E-B SoCo

Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…

12 hours ago

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

21 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

24 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

24 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

24 hours ago